Why the study?
Does levosimendan improve outcomes compared to dobutamine in patients with acute, decompensated heart failure?
Population
Patients with acute, decompensated heart failure
Comparison
Levosimendan 6-24 mug/kg intravenous bolus… vs Dobutamine
Design
Review
Authors
Loading...
May support levosimendan over dobutamine in acute decompensated HF; hypothesis-generating and leaves open need for confirmatory RCTs.
Does levosimendan improve outcomes compared to dobutamine in patients with acute, decompensated heart failure?
Levosimendan appears to be a safe and effective alternative to dobutamine for treating acute, decompensated heart failure in patients unresponsive to diuretics and vasodilators.
Earl et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: